JNJ 63723283

Drug Profile

JNJ 63723283

Alternative Names: JNJ-63723283

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Multiple myeloma
  • Phase I/II Prostate cancer; Solid tumours

Most Recent Events

  • 02 Mar 2018 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Spain, USA (IV) (NCT03431350) (EudraCT2017-003552-23)
  • 13 Feb 2018 Janssen Research & Development plans a phase I/II trial for Prostate cancer in USA and Canada , (NCT03431350)
  • 25 Oct 2017 Phase-II/III clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Belgium (IV) (EudraCT2017-002611-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top